Omalizumab rescue therapy in refractory status asthmaticus

Department

Medicine

Document Type

Article

Publication Title

The Journal of Asthma

Abstract

Introduction: Refractory status asthmaticus (RSA) is a severe, life-threatening form of asthma exacerbation that persists despite aggressive treatment with systemic corticosteroids, bronchodilators, and other supportive measures. Omalizumab, a monoclonal antibody that targets IgE, has been approved for treating severe allergic asthma and is effective in reducing the frequency of exacerbations and improving asthma control. Limited evidence exists regarding the use of Omalizumab in RSA, but some studies have suggested that it may have a role in its management.

Case: A 39-year-old male with a decade-long history of asthma presented to the emergency department intubated and unresponsive to pharmacological therapy. The patient's IgE levels were elevated, and Omalizumab was administered after a comprehensive evaluation. The patient made a dramatic recovery and was successfully weaned off the ventilator within 24 h of receiving Omalizumab. He made an uneventful recovery and was discharged home on Omalizumab once every two weeks with regular follow-ups.

Discussion and conclusion: Per our literature search, only 3 cases have been reported where Omalizumab was administered to patients with RSA to wean them off ventilatory support successfully. This case study adds to the existing data on the potential benefits of Omalizumab in managing RSA. It suggests it may be a valuable treatment option for patients who do not respond to standard therapy. However, further research is needed to determine the efficacy and safety of Omalizumab in this population.

First Page

2243

Last Page

2247

DOI

10.1080/02770903.2023.2233606

Volume

60

Issue

12

Publication Date

12-1-2023

Medical Subject Headings

Male; Humans; Adult; Omalizumab (therapeutic use); Status Asthmaticus (drug therapy); Asthma; Antibodies, Monoclonal, Humanized (therapeutic use); Immunoglobulin E; Anti-Asthmatic Agents; Treatment Outcome

PubMed ID

37427873

Link to Full Text

Share

COinS